H.C. Wainwright Remains a Buy on Lipocine

By Jason Carr

H.C. Wainwright analyst Corey Davis reiterated a Buy rating on Lipocine (NASDAQ: LPCN) today and set a price target of $25. The company’s shares closed yesterday at $3.99.

According to TipRanks.com, Davis is a 4-star analyst with an average return of 5.1% and a 47.3% success rate. Davis covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, Aquinox Pharmaceuticals, and Infotek Pharmaceuticals.

Currently, the analyst consensus on Lipocine is Strong Buy and the average price target is $24.33, representing a 509.8% upside.

In a report issued on June 20, Roth Capital also reiterated a Buy rating on the stock with a $38 price target.

The company has a one year high of $5.90 and a one year low of $2.51. Currently, Lipocine has an average volume of 353.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Lipocine, Inc. engages in the research and development of treatment for use in men’s and women’s health through proprietary drug delivery technologies. It focuses on oral testosterone replacement therapy and preterm birth prevention. The company was founded on July 24, 2013 and is headquartered in Salt Lake City, UT.